Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India

T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



30th August 2024

BSE Limited	National Stock Exchange of India	
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 th Floor, Plot No. C/l,	
Dalal Street,	G block, Bandra Kurla Complex,	
Mumbai - 400 001	Bandra (East), Mumbai - 400 051	
Scrip Code: BSE - AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ	

Sub.: Intimation regarding issuance of Letter of Confirmation under Regulation 39(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Dear Sir/Madam,

Pursuant to Regulation 39(3) of the SEBI LODR Regulations and in terms of SEBI Circular No. SEBI/HO/MIRSD/ MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022, the Company has approved issuance of "Letter of Confirmation" on 30th August 2024 in lieu of share certificate(s), which were reported lost by the following shareholder:

Name of Shareholder	Folio No	Old Certificate No.	New Certificate No.	Distinctive Nos.	Shares
AOTE ASHISH	0005363	380	19562	336001-336750	750
ANNAJI		19422	19562	88086082-88086456	375

Kindly take the above information on record.

Thanking you,

Yours faithfully,

Gaurang Shah

Sr. VP- Legal & Company Secretary